Business Wire (Wed, 2:53PM)
Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
181 people get GEVA articles and Market Currents by email alert.
Get email alerts on GEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 15, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Mar 26, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 30, 2013)
-
-
Business Wire (Jan 9, 2013)
-
-
Business Wire (Jan 3, 2013)
-
Business Wire (Jan 3, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
3 Healthcare Companies With Recent Insider BuysMarkus Aarnio • Tue, Jul 17, 2012 -
-
-
-
-
Rare Disease Stocks With Takeover PotentialJessica King Holden • Tue, Apr 24, 2012 -
-
-
-
10 Rallying Stocks That Meet Warren Buffett's Management CriteriaFollow My Alpha • Tue, Nov 8, 2011
-
Business Wire (Wed, 2:53PM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Mar 26, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 30, 2013)
-
Business Wire (Jan 9, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Nov 19, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 6, 2012)
GEVA vs. ETF Alternatives
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 20, 7:54 AM The FDA grants Synageva BioPharma (GEVA) Breakthrough Therapy designation for sebelipase alfa, a treatment for early onset acid lipase deficiency. Earlier this month, JPMorgan expressed some skepticism based on what the bank says is a fairly low level of disease awareness (even among specialists). (PR) Comment! [Healthcare]
- Friday, May 10, 12:48 PM Synageva BioPharma (GEVA -5.5%) slips today after JP Morgan cut the shares to Neutral and lowers its price target from $57 to $50. The firm cites concerns over enrollment challenges related to its ongoing Phase 3 trial of sebelipase alfa in late-onset LAL Deficiency, saying that awareness of the disease is fairly low, even among specialists, so patient identification could take a bit longer. Comment! [Healthcare, On the Move]
- Tuesday, May 7, 8:02 PM Synageva (GEVA): Q1 EPS of -$0.54 beats by $0.16. Revenue of $5.12M beats by $2.56M. (PR) Comment! [Earnings, Breaking News]
- Tuesday, March 12, 2:59 PM Synageva BioPharma (GEVA -4.3%) slides after its Q4 beats on revenue but comes up short on a per share basis. Despite the miss, Piper Jaffray lifts its price target from $53 to $57, citing optimism over upcoming Phase 1/2 data on LAL-D. Wedbush also ups its target to $55 as well. Comment! [Healthcare, On the Move, Earnings]
- Monday, March 11, 4:29 PM Synageva (GEVA): Q4 EPS of -$0.62 misses by $0.02. Revenue of $4.8M beats by $2.48M. (PR) Comment! [Earnings, Breaking News]
- Monday, February 11, 2:05 PM Synageva BioPharma (GEVA +0.9%) says the first patient has been initiated treatment in its Phase 3 study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency. Once fully initiated, the trial will enroll 50 child and adult patients with late onset LAL Deficiency. Comment! [Healthcare, On the Move]
-
Friday, January 4, 9:10 AM
Premarket gainers: FOLD +10%. ALU +7%. HNR +6%. GEVA +5%.
Losers: ARAY -29%. Comment! [On the Move] -
Tuesday, July 10, 2012, 9:10 AM
Premarket gainers: VRNG +11%. ASML +8%. CALL +7%. GEVA +5%.
Losers: MAKO -40%. JRCC -17%. AMBT -11%. BZH -9%. AMD -9%. CHTP -7%. AMAT -6%. Comment! [On the Move] - Friday, June 29, 2012, 12:41 PM ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%). Comment! [Healthcare, On the Move]
- Thursday, January 5, 2012, 11:15 AM Shares of Synageva BioPharma (GEVA) reverse an AH decline yesterday that followed its announcement of a $60M stock offering, gaining 12.8% today to touch 52-week highs. Comment! [On the Move, Healthcare]
- Wednesday, January 4, 2012, 4:33 PM Drug developer Synageva BioPharma (GEVA) drops 2.1% AH after announcing a $60M stock offering - equal to 13.6% of its market cap as of today's close. The company only says it plans to use the proceeds for "general corporate purposes." (prospectus) Comment! [Healthcare, On the Move]
- Wednesday, December 14, 2011, 10:06 AM Synageva BioPharma (GEVA +5.1%) gets a kickstart with a timely initiation from Wedbush to Outperform with a price target of $32. Analysts see Phase I/II releases in 2012 building on positive results with the firm's treatment for Wolman disease. Shares of GEVA hit a 52-week high off the momentum. Comment! [On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
GEVA - 17 new highs and up 39.76% in the last month - Relative strength Index 82.22% - View all 2 replies
-
-
Jim Van Meerten: No, I screened for stocks hitting the most frequent new highs
LATEST REPLIES
-
Jim Van Meerten
GEVA - 17 new highs and up 39.76% in the last month - Relative strength Index 82.22% - View all 2 replies
-
-
Jim Van Meerten: No, I screened for stocks hitting the most frequent new highs